Filter Results
:
(830)
Show Results For
-
All HBS Web
(830)
- People (3)
- News (200)
- Research (576)
- Events (1)
- Multimedia (1)
- Faculty Publications (428)
Show Results For
-
All HBS Web
(830)
- People (3)
- News (200)
- Research (576)
- Events (1)
- Multimedia (1)
- Faculty Publications (428)
- 23 Jan 2018
- Video
Dr. Marlene Krauss: Health Care Visionary
- 14 Nov 2017
- First Look
New Research and Ideas: November 14, 2017
through three examples: the design of medical residency matching programs, a scrip system to allocate food donations to food banks, and the recent "Incentive Auction" that reallocated wireless spectrum from television broadcasters to...
View Details
Keywords:
Carmen Nobel
- January 2024
- Article
A Cost Model for a Low Threshold Clinic Treating Opioid Use Disorder
By: Sarah E. Wakeman, Elizabeth Powell, Syed Shehab, Grace Herman, Laura Kehoe and Robert S. Kaplan
The US fee-for-service payment system under-reimburses clinics offering access to comprehensive treatments for opioid use disorder (OUD). The funding shortfall limits a clinic’s ability to expand and improve access, especially for socially marginalized patients with...
View Details
Wakeman, Sarah E., Elizabeth Powell, Syed Shehab, Grace Herman, Laura Kehoe, and Robert S. Kaplan. "A Cost Model for a Low Threshold Clinic Treating Opioid Use Disorder." Journal of Behavioral Health Services & Research 51, no. 1 (January 2024): 22–30.
- October 19, 2015
- Article
Getting Bundled Payments Right in Health Care
By: Robert S. Kaplan, Derek A. Haas, Dereesa Reid, Jonathan Warsh and Michael E. West
Bundled payments—single payments that cover all the care for a patient’s medical condition or treatment over a specified timeframe—are increasingly being deployed to motivate the delivery of better patient outcomes at lower costs. Hoag Orthopedic Institute (HOI), a...
View Details
Kaplan, Robert S., Derek A. Haas, Dereesa Reid, Jonathan Warsh, and Michael E. West. "Getting Bundled Payments Right in Health Care." Harvard Business Review (website) (October 19, 2015). (A collaboration of the editors of Harvard Business Review and the New England Journal of Medicine.)
- April 2009 (Revised November 2012)
- Case
Sermo, Inc.
By: Thomas R. Eisenmann and Lars Peter Christian Nielsen
Sermo operates the leading online professional network for physicians in the United States. Doctors use Sermo free of charge to post surveys regarding diagnostic and treatment concerns and to discuss these concerns, as well as challenges with managing their practices....
View Details
Keywords:
Entrepreneurship;
Health Care and Treatment;
Knowledge Sharing;
Two-Sided Platforms;
Conflict and Resolution;
Social and Collaborative Networks;
United States
Eisenmann, Thomas R., and Lars Peter Christian Nielsen. "Sermo, Inc." Harvard Business School Case 809-142, April 2009. (Revised November 2012.)
- 22 Jun 2020
- News
On Track: Health Care, Patient Data, and Provider Performance
- 29 Jun 2013
- News
Hospital operators and Obamacare: Prescription for change
- 2020
- Working Paper
Mission-Oriented Research in a National Emergency: Lessons from the Office of Scientific Research and Development in World War II
By: Daniel P. Gross and Bhaven N. Sampat
Since the beginning of the present COVID-19 pandemic, policymakers, researchers, and journalists have made repeated comparisons to World War II. In ongoing research, we have been studying the effects of the World War II research effort, which included a major medical...
View Details
- 15 Jul 2013
- Research & Ideas
Five Imperatives for Improving Health Care
Innovation in health care treatment seems to far outpace innovation in health care business management. Just ask President Obama—two weeks ago he delayed enactment of a key provision of the new health care law for fear its requirements...
View Details
- October 2009 (Revised August 2014)
- Case
Tengion: Bringing Regenerative Medicine to Life
By: Elie Ofek and Polly Ross Ribatt
Tengion is a young biotech company that is at the frontier of regenerative medicine—a nascent field that seeks to promote the creation of new cells and tissue to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. In late...
View Details
Keywords:
Decision Choices and Conditions;
Financial Crisis;
Entrepreneurship;
Health Care and Treatment;
Technological Innovation;
Product Launch;
Product Development;
Research and Development;
Biotechnology Industry;
United States
Ofek, Elie, and Polly Ross Ribatt. "Tengion: Bringing Regenerative Medicine to Life." Harvard Business School Case 510-031, October 2009. (Revised August 2014.)
- April 2017
- Supplement
Imprimis (B)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A). It describes the company’s decision to enter into the pharmaceutical compounding business in 2013–2014. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients’...
View Details
Keywords:
Healthcare;
Drug Compounding;
Drug Development;
Pharmaceuticals;
Small Business;
Decision-making, Business Model;
Mark Baum;
Imprimis;
Decision Making;
Strategy;
Health Care and Treatment;
Policy;
Pharmaceutical Industry;
United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (B)." Harvard Business School Supplement 717-496, April 2017.
- April 2012 (Revised February 2013)
- Case
Learning About Reducing Hospital Mortality at Kaiser Permanente
By: Anita Tucker
In 2011, Kaiser Permanente Northern California (KPNC) region's efforts to reduce mortality in their 21 hospitals is showing promise. They developed and launched a region-wide initiative to improve the treatment of sepsis, a serious and often deadly medical condition....
View Details
Keywords:
Change Management;
Health Care and Treatment;
Performance Improvement;
Health Industry;
California
Tucker, Anita. "Learning About Reducing Hospital Mortality at Kaiser Permanente ." Harvard Business School Case 612-093, April 2012. (Revised February 2013.)
- 23 Oct 2015
- News
The Mayo Clinic Model for Running a Value-Improvement Program
- April 2019
- Case
Barber Cardiosystems
By: Ranjay Gulati and Paul S. Myers
Barber Cardiosystems, based in Melbourne, Australia, designs and manufactures therapeutic devices used for treatment of coronary conditions. Over four decades, it has grown to be among the top 200 medical device companies in the world. It competes against much larger...
View Details
Keywords:
Organizational Behavior;
Strategic Alignment;
Cost Management;
Performance Productivity;
Organizational Culture;
Motivation and Incentives;
Organizational Design;
Strategy;
Leadership;
Medical Devices and Supplies Industry;
Australia
Gulati, Ranjay, and Paul S. Myers. "Barber Cardiosystems." Harvard Business School Brief Case 919-505, April 2019.
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,...
View Details
Keywords:
Health Care and Treatment;
Business Model;
Leadership;
Pharmaceutical Industry;
Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
- August 2023 (Revised May 2024)
- Case
Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations
By: Satish Tadikonda and Amanda McEwen
The success or failure of Dicerna Pharmaceuticals (Dicerna) as an emerging pharmaceutical company would likely hinge on its lead drug candidate Nedosiran and the company’s ability to see it successfully through clinical development. Ralf Rosskamp, Chief Medical...
View Details
Tadikonda, Satish, and Amanda McEwen. "Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations." Harvard Business School Case 824-018, August 2023. (Revised May 2024.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,...
View Details
Keywords:
Health Testing and Trials;
Health Care and Treatment;
Business Model;
Problems and Challenges;
Pharmaceutical Industry;
Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- 28 Mar 2023
- Research & Ideas
The FDA’s Speedy Drug Approvals Are Safe: A Win-Win for Patients and Pharma Innovation
and effective in preventing severe disease, and their accelerated review will go down in history as having saved millions of lives. But COVID vaccines weren’t the first medical products to be brought to market through an expedited...
View Details
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,...
View Details
Keywords:
Health Care and Treatment;
Business Model;
Production;
Business Strategy;
Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- 08 Jun 2015
- Working Paper Summaries